WO1994003635A1 - Rapid amplification and detection of nucleic acids - Google Patents
Rapid amplification and detection of nucleic acids Download PDFInfo
- Publication number
- WO1994003635A1 WO1994003635A1 PCT/GR1992/000015 GR9200015W WO9403635A1 WO 1994003635 A1 WO1994003635 A1 WO 1994003635A1 GR 9200015 W GR9200015 W GR 9200015W WO 9403635 A1 WO9403635 A1 WO 9403635A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- sequence
- biotin
- target
- seq
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 90
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 56
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 56
- 230000003321 amplification Effects 0.000 title claims abstract description 34
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 34
- 238000001514 detection method Methods 0.000 title abstract description 17
- 239000013615 primer Substances 0.000 claims abstract description 122
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 100
- 239000000523 sample Substances 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 91
- 108020004414 DNA Proteins 0.000 claims abstract description 52
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 52
- 229960002685 biotin Drugs 0.000 claims abstract description 50
- 235000020958 biotin Nutrition 0.000 claims abstract description 50
- 239000011616 biotin Substances 0.000 claims abstract description 50
- 238000006243 chemical reaction Methods 0.000 claims abstract description 44
- 239000002773 nucleotide Substances 0.000 claims abstract description 37
- 239000002777 nucleoside Substances 0.000 claims abstract description 36
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 36
- 239000001226 triphosphate Substances 0.000 claims abstract description 32
- 235000011178 triphosphate Nutrition 0.000 claims abstract description 32
- -1 nucleoside triphosphates Chemical class 0.000 claims abstract description 28
- 239000003155 DNA primer Substances 0.000 claims abstract description 11
- 239000002987 primer (paints) Substances 0.000 claims abstract description 6
- 230000000295 complement effect Effects 0.000 claims description 20
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 108091027568 Single-stranded nucleotide Proteins 0.000 claims description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 108090001008 Avidin Proteins 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims description 5
- 102100034343 Integrase Human genes 0.000 claims description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 2
- 238000009877 rendering Methods 0.000 claims 3
- LRDIEHDJWYRVPT-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 LRDIEHDJWYRVPT-UHFFFAOYSA-N 0.000 claims 1
- 102000003992 Peroxidases Human genes 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 6
- 239000000047 product Substances 0.000 description 35
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 238000000137 annealing Methods 0.000 description 12
- 241000700605 Viruses Species 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 8
- 238000004925 denaturation Methods 0.000 description 7
- 230000036425 denaturation Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000001351 cycling effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 101710136739 Teichoic acid poly(glycerol phosphate) polymerase Proteins 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 108020001019 DNA Primers Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 239000005549 deoxyribonucleoside Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- IYKNGWWPNRDDHK-ONEGZZNKSA-N [[5-[2,4-dioxo-5-[(e)-3-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]prop-1-enyl]pyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical group O1C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)CC1N1C(=O)NC(=O)C(\C=C\CNC(=O)CCCCC2C3NC(=O)NC3CS2)=C1 IYKNGWWPNRDDHK-ONEGZZNKSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006642 detritylation reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004374 forensic analysis Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000012985 polymerization agent Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Definitions
- This invention relates to the rapid amplification and detection of nucleic acids.
- the invention provides improved methods for amplifying small amounts of nucleic acids in a sample in which the
- ⁇ amplifcation steps are conducted at the same temperature or, alternatively, at only two different temperatures.
- the invention provides improved methods for detecting the amplified nucleic acids in which the detection signal is boosted.
- the invention is expected to be useful in a wide variety of fields, including scientific, clinical, and forensic analysis. In one specific embodiment, it is particularly useful in the detection of human immunodeficiency virus type 1 (HIV-1) , the causative HIV-1 (HIV-1) , the causative HIV-1 (HIV-1) , the causative HIV-1 (HIV-1) , the causative HIV-1 (HIV-1) , the causative HIV-1 (HIV-1) , the causative HIV-1 (HIV-1) , the causative HIV-1 (HIV-1)
- the ability to detect exceeding small amounts of a nucleic acid in a sample generally requires the amplification of the amount of the target nucleic acid. °L Q This is especially important for the detection of human retroviruses, where positive samples may contain only 5-10 target molecules in 10 6 cells.
- the preferred method for amplifying target DNA has been the polymerase chain reaction (PCR) technique.
- PCR polymerase chain reaction
- the 2S technique has been described in U.S. Patent Nos. 4,683,195, issued July 28, 1987 to Mullis, et al., 4,683,202, issued July 28, 1987 to Mullis, 4,800,159, issued January 24, 1989 to Mullis, et al., 4,889,818, issued December 26, 1989 to Gelfand, et al., and 4,902,624, issued February 20, 1990 to Columbus, et al., all of which are incorporated herein by S reference.
- the PCR reaction involves the use of a pair of specific oligonucleotide primers to initiate DNA synthesis on a target DNA template.
- Two oligonucleotide primers are used for each double-stranded sequence to be amplified.
- the target sequence is denatured into its complementary strands.
- Each of the primers which are sufficiently complementary to a portion of each strand of the target sequence to hybridize with it, anneals to one of the strands.
- the primers are extended, using nucleosides S" in the sample and a polymerization agent, such as heat- stable Tag DNA polymerase. This results in the formation of complementary primer extension products, which are hybridized to the complementary strands of the target sequence.
- the primer extension products are then separated from the template strands, and the process is repeated until the desired level of amplification is obtained. In subsequent cycles, the primer extension products serve as new templates for synthesizing the desired nucleic acid sequence.
- the original target DNA can be amplified exponentially according to the formula 2 n , where n is the number of cycles.
- 25 cycles for example, would result in a 3.4 x 10 7 -fold amplification.
- ⁇ the efficiency of each cycle is less than 100%, the actual amplification after 25 cycles is about 1-3 x 10 6 -fold.
- the size of the amplified region is generally about 100-400 base pairs, although stretches of up to 2 kb can be amplified. See Keller and Manak, DNA Probes (New York: Stockton Press, 1989), pgs. 215-216.
- Gelfand, et al. discloses a denaturing temperature range of about 90*-105'C, preferably 90*-100°C,
- the PCR technique has been modified to permit the 30 amplification of viral RNA. See Murakawa, et al., DNA, 7:287-295 (1988), which is incorporated herein by reference.
- the article discloses the amplification of sequences from HIV-1 RNA templates for the identification of HIV-1 in peripheral blood and tissue samples obtained from AIDS and ARC patients. Total nucleic acid is isolated
- RNA sequence S from infected cells, and the DNA is digested with RNase- free DNase so that it does not contribute to the final PCR product.
- a cDNA copy of a target sequence of the viral RNA is synthesized, using the PCR primers and reverse transcriptase. The one primer complementary to the RNA
- Nonradioactive labeled probes are generally more desirable because they obviate the need for special handling procedures. However, they may not ao generate as intense a signal, or the signal may be obscurred by background "noise.” Thus, there is a need for enhancing the intensity of the signal in such probes.
- the PCR technique is a revolutionary one, and it is widely used. Nevertheless, it does have significant 5 drawbacks. The most serious of these is nonspecific hybridization, which results in false positives. Avoiding nonspecific hybridization requires ultrapure reagents. Unfortunately, for most clinical and diagnostic applications, it is desirable to use "dirty" samples, which
- the present invention overcomes these drawbacks of the PCR technique, and it provides an improved detection system.
- the invention provides methods for the rapid
- the invention provides amplification methods
- the invention provides improved methods of detecting the amplified nucleic acids through a two-stage signal amplification.
- a further object of the invention is to provide 5 primer pairs for use in amplifying a nucleic acid sequence of HIV-1 DNA.
- a still further object is to provide a probe for use in detecting a nucleotide sequence complementary to a target nucleic acid sequence of HIV-l DNA.
- the present invention provides a method for ao amplifying a target nucleic acid sequence in a sample.
- the sequence is part of a nucleic acid, which the sample is suspected of containing.
- the target nucleic acid is DNA, most preferably HIV-l DNA.
- Nucleoside triphosphates, primer pairs consisting (jS of two oligonucleotide primers, and a nucleic acid polymerase are added to the sample.
- Each primer is an oligonucleotide having a region that is complementary to and hybridizes with a different strand of the target sequence. It is effective as an initiator for nucleoside polymerization.
- the nucleic acid in the sample is denatured so that separate strands of the target nucleic acid sequence are formed.
- the S denaturing is accomplished by heating the sample to about 95 ⁇ C.
- the primers anneal (hybridize) to the separate strands of the target sequence.
- the primers and the nucleic acid polymerase initate the synthesis of primer extension products, formed by the nucleosides attaching to the primer and forming a polymer, using the target sequence
- the primer extension products are annealed or hybridized to the strands.
- the primer extension products are then separated from the strands to become templates for the primers, and the cycle is repeated, with new primer extension products being formed.
- the reaction is allowed to continue for a sufficient number of cycles until the desired amplification of the target nucleic acid sequence has been accomplished.
- the primers are chosen so that they bind strongly to the strands of the target sequence, but the extension from each primer binds as weakly to the strand.
- the cycling occurs at two different temperatures.
- the reaction temperature is maintained in a range from about 68*C to about 82*C (preferably about 70*C) and appropriate reaction 3 conditions are maintained to form the primer extension products. These are separated from the strands by raising the temperature to a range of about 88 * C to about 96*C (preferably about 90*C) to produce single-stranded molecules. The temperature is then lowered back to the previously mentioned range, permitting the primers to S anneal to the single-stranded molecules and primer extension products to be synthesized, using the single- stranded molecules as templates. The temperature cycling is repeated a sufficient number of times to obtain the desired amplification of the target nucleic acid sequence.
- the invention also provides methods for detecting or measuring a target nucleic acid sequence in a sample, based upon the amplification methods discussed above. In these methods, some of the nucleoside triphosphates are biotin-labeled. This produces nucleotide sequences that
- ⁇ £ are copies of the target sequence which contain one or more biotin-labeled nucleotides. Such sequences are rendered single-stranded and contacted with immobilized probes. Each of the probes is a single-stranded polynucleotide attached to a solid support and capable of hybridizing with
- the probes are contacted with the sample for a sufficient time and under appropriate hybridizing conditions to permit the polynucleotides to hybridize with the single-stranded nucleotide sequences.
- the presence of the biotin in the bound complexes is then detected or measured.
- the biotin is detected by contacting the bound complexes with a detectable moiety that binds to biotin, such as avidin-horseradish peroxidase, and then detecting
- the detectable moiety i.e., the horseradish peroxidase.
- the detecting step is accomplished by contacting the bound complexes with a first moiety that binds to biotin, such as avidin.
- a second moiety comprising biotin bound to $ detectable moity, such as horseradish peroxidase, is then added.
- the biotin in this second moiety binds to the first moiety.
- the detectable moiety is then detected. This provides a two-stage amplification of the signal.
- kits for detecting ⁇ or measuring the presence of a target nucleic acid sequence in a sample contain biotin-labeled nucleoside triphosphates and a primer pair specific for the particular target sequence sought to be detected or measured.
- the kit further comprises a probe that is ⁇ S specific for the target sequence. It may also contain a nucleic acid polymerase, reagents for detecting or measuring the biotin, denaturing reagents, and/or controls.
- the target nucleic acid sequence is HIV-l DNA.
- the primer pair ao comprises the nucleotide sequences
- the probe comprises the nucleotide sequence
- the invention provides improved methods for amplifying and detecting nucleic acids.
- the target nucleic acid may be single or double-stranded DNA or RNA from any organism. Such organisms include plants, animals, and microorganisms, such viruses, viroids, mycoplasma, bacteria, and fungi.
- the viruses include DNA and RNA viruses.
- the viruses are retroviruses, and in a particularly preferred embodiment, they are the AIDS-related viruses (including HIV-l and HIV- 2) .
- the term "animals" includes mammals, and, in a preferred embodiment, the target nucleic acid is mammalian nucleic acid, such as mitochondrial or genomic DNA or the various types of RNA. Such nucleic acid further includes human cellular oncogene sequences and human structural gene sequences.
- the sample may be anything that contains nucleic acid, obtained from a source by techniques known to those skilled in the art. It may be further processed by known techniques, such as being subjected to extraction procedures, to render it in a form usable in the method of the invention.
- the method of the present invention can be applied to determine if a patient has been infected by a virus.
- a sample of body fluid or tissue that contains the virus is obtained from the patient.
- the sample should contain cells that are capable of being infected by the virus or should contain body fluid in which the virus or viral nucleic acid is known to accumulate.
- the viral nucleic acid is extracted from the sample by known techniques.
- a target nucleotide sequence within the target nucleic acid is selected so as to provide a target of sufficient specificity and uniqueness in order to be identified and distinguished from other nucleic acid molecules in the sample. Among other things, it will be selected on the basis of a nucleotide base sequence specific to the organism. For many viruses, in particular those that mutate at high rates, it is advisable to select a target sequence from a well-conserved region of the viral genome.
- the target nucleotide sequence may consist of from about 50 to about 4000 base pairs, but preferably consists of about 55 to about 200 base pairs, and most preferably consists of about 60 to about 100 base pairs.
- the preferred target sequences are the c nucleotide sequence 1317-1379 of pHXB2 and 331-530 of pHXB2, depending upon which primer pair of the invention is used to amplify the sequence.
- the target sequence is amplified in a reaction that occurs at a single temperature, after the initial denaturation of the nucleic acid, in contrast to the three different temperatures in the PCR technique.
- CER Continuous Enzyme Reaction
- certain reagents are added to the sample that contains the o target nucleic acid.
- nucleoside triphosphates including biotinylated nucleotide triphosphates, primer pairs, and a nucleic acid polymerase are added.
- they are added as part of a buffered solution.
- Each primer is an oligonucleotide having a region that is complementary to and hybridizes with a different strand of the target sequence. It is effective as an initiator for nucleoside polymerization. Preferably, the length of each primer is approximately 15- 25 nucleotides.
- the target nucleic sequence if it is double- stranded, is then separated into single strands by known techniques.
- the nucleic acid is denatured by heating the sample to about 95*C.
- the target sequence may be denatured before the other reagents are added to the sample, although it is preferable to denature it afterwards.
- each of the oligonucleotide primers anneals (hybridizes) to each of the strands of the denatured target sequence;
- primer extension products are synthesized from the nucleoside triphosphates, with the systhesis being initiated by the primer and catalyzed by the nucleic acid polymerase; and (3) a portion of the extension products, which are hybridized to the strands of the target sequence, separate spontaneously from the strands.
- the separated extension products become templates for the primers, and the cycle is repeated.
- Such reaction conditions include maintaining the reaction temperature somewhere in the range from about 68*C to about 80 * C. Preferably, the temperature is maintained at about 75 * C.
- the reaction is permitted to proceed for a sufficient period of i e so that the cycle is repeated about 10 to about 25 cimes. This will occur over a time ranging from about 1.0 hours to about 2.5 hours. 5 Generally, the longer reaction time is preferred.
- nucleoside triphosphates are readily available commercially or can be synthesized by those skilled in the art.
- deoxyribonucleoside triphosphates are ⁇ o used.
- nucleoside triphosphates or deoxyribonucleoside triphosphates are labeled with biotin. This permits the incorporation of a reporter molecule into the amplified sequences, which can
- biotin-labeled nucleoside triphosphates can be synthesized by known techniques or are commercially available.
- the preferred biotin-labeled nucleoside triphosphate is Bio- dUTP.
- the labeled nucleosides are used in a concentration of about 10 uM to about 5mM, and preferably from about 0.1 mM to about 0.5 mM.
- the polymerizing agent is any polymerase for nucleic acid.
- it is Tag polymerase, which is heat stable under these reaction conditions.
- the primer pairs consist of two oligonucleotide primers.
- Each primer is an oligonucleotide having a region that is complementary to and hybridizes with a different strand of the target sequence, and is effective as an initiator (primer) for nucleoside polymerization.
- the primers of the invention are selected so as to meet two requirements. First, they must bind strongly to the strands of the target sequence to allow binding at a
- the product from the extension of the primers, which is synthesized from the nucleosides in the presence of the polymerase is the least stable of a series of products which were initially selected and more likely
- the term "bind strongly" and variations thereof means adequately stable single-stranded 16DNA-primer hybrids are formed at the high temperature of
- the ratio of G and C to A and T in the primers ranges from about 1.5:1 to about 3.0:1.
- the ratio is about 3.0:1.
- Td Q dissociation
- Tm melting temperature
- Tm 81.5° + 16.6 log Ci + 0.41 (% C+G) - 0.72 (% forma ide) - 82°/n - 1.5 (% mismatch)
- n is the number of nucleotides.
- specific primers which we call HOPE 1 and HOPE 2 are preferred:
- HOPE 1 5' GAAGGAGCCA CCCCACAAG 3' (SEQ ID NO: 1)
- HOPE 2 3' CCCCCCTGTA GTTCGTCGG 5' (SEQ ID NO: 2)
- the temperature should be high enough so that a substantial portion of the target DNA is found in single-
- the concentration of the primers should be high enough so as to favor single-stranded DNA-primer hybrid formation.
- the GC content of the primers should be such as to allow an adequately stable single-stranded DNA-primer hybrid to be formed at the high temperature chosen.
- the primer extension product on the contrary, should be as unstable as possible so that the probability for the two strands to dissociate spontaneously is as high as possible.
- the polymerizing agent should be able to efficiently polymerize dNTPs at the high temperature chosen and also to incorporate the dNTP analogue used as a label onto DNA strands.
- the cycle of primer annealing, primer extension, and extension product denaturing occurs from about 10 to about 25 times.
- the time period for this to occur is approximately 0.5 hours to overnight.
- asymmetric concentrations of the primers are used. That is, the concentration of one of the primers exceeds that of the other by a factor of about 10 3 to 1, and preferably by c about 10 2 to about 1. This permits the build up of only one instead of two primer extension products. Therefore, there is only a limited risk of DNA-DNA co plexing during hybridization. Instead, the product DNA will bind to the primer or the probe that is used for detection of the S " amplified DNA. This enhances both the specificity and sensitivity of the assay.
- the nucleic acid to be amplified is RNA, certain modifications are made.
- the RNA template in infected cells is either viral RNA or packaged virion RNA. Total nucleic acid is isolated in crude form by known
- Residual DNA may be digested with RNase-free DNase so that it does not contribute to the amplified sequences.
- a cDNA copy of a target ribonucleotide sequence in the target RNA is synthesized, lo using the primers and reverse transcriptase.
- the primer complementary to the target sequence serves to initate cDNA synthesis.
- the single-stranded cDNA product can be amplified after heat inactivation of the reverse transcriptase and adjustment of the reaction conditions to
- the amplification of the target nucleic acid sequence occurs at two different temperatures.
- the primer annealing and extension steps occur at one temperature, and the Sf ⁇ denaturing of the primer extension products occurs at another temperature.
- ACR Accelerated Chain Enzyme Reaction
- the reaction temperature is maintained at a point in the range from about 68*C to about 82*C for primer annealing and extension.
- the reaction temperature for these steps of the cycle is about 70*C.
- the primer extension products are separated from the target sequence strands or other extension products by raising the temperature to a range of about 88 * C to about 0 96*C. This denatures the extension products from the template, producing single-stranded molecules that serve as further templates when the temperature is lowered.
- the denaturing step occurs at a temperature of about 90 • C.
- the cycling between these two temperatures is repeated about 10 to about 25 times.
- the reaction time for these steps is from about 0.5 hours to about 3 hours. Generally, the time is about 1.5 hours.
- the preparation of the sample and the initial reaction mixture is essentially the same as in the single temperature method.
- the target nucleic acid sequence is also denatured in the same manner. This method also lends itself to the use of asymmetric concentrations of primers and to the amplification of RNA as discussed previously.
- primers for any given target sequence are determined as discussed above with respect to the single temperature embodiment.
- the primers will have the same general characteristics mentioned above.
- HOPE 1 and HOPE 2 primers are preferred.
- two other primers, which we designate NIDA 1 and NIDA 2 are preferred. These primers comprise the following sequences:
- NIDA 1 5' GACATCGAGC TTGCTAGAAG 3' (SEQ ID NO: 4)
- NIDA 2 3' GGTGACGAAT TCGGAGTTAT 5' (SEQ ID NO: 5)
- the invention comprises a method for detecting or measuring a target nucleic acid in a sample.
- the target sequence is amplified according to the methods discussed above, wherein some of the nucleoside triphosphates are biotin-labeled. This produces nucleotide sequences that are copies of the target sequence and contain one or more biotin-labeled nucleotides.
- the amplified sequences which will be double-stranded, are then rendered single-stranded by known techniques, preferably heat denaturation at a temperature of about 88*C to about 96*C.
- the sample is then contacted with immobilized probes.
- probes are single-stranded polynucleotides attached to a solid support. Each one is capable of hybridizing with one of the single-stranded nucleotide sequences.
- the probes are contacted with the sample for a sufficient time and under appropriate hybridizing conditions known to those skilled in the art to permit the polynucleotides to hybridize with the single- stranded nucleotide sequences. This forms bound complexes of the polynucleotides and the single-stranded nucleotide sequences.
- the probes can be prepared by standard techniques known to those skilled in the art, given the particular target sequence and the teachings contained herein.
- the nucleic acid is HIV-l DNA
- the preferred probe comprises the sequence 5' TTTAAACACC ATGCTAAACA CAGT 3' (SEQ ID NO: 3), which we call the HOPE 3 probe.
- the HOPE 3 probe may also be used with a pyri idine spacer at the 5'end.
- the spacer is CTCTC, in which case we call the probe HOPE 4.
- the solid support may be any solid material to which the probe may be attached. Such material includes filters, resins, beads, cubes, and microtiter plates.
- the solid supports are the wells in plastic 5 microtiter plates, such as polystyrene microtiter plates.
- the probe is first chemically coupled to a protein carrier, such as bovine serum albumin, which is then immobilized onto polystyrene microtiter plate wells. See Running and Urdea, BioTechniques. 8:276-277 (1990) and ⁇ 0 Nagata, et al., FEBS Letters. 183:379-382 (1985), both of which are incorporated herein by reference.
- the single-stranded polynucleotide of the probe is attached to the solid support covalently or noncovalently by means known to those skilled in the art.
- the solid support covalently or noncovalently by means known to those skilled in the art.
- the probe is chemically coupled to a protein, such as bovine serum albumin, or other carrier, such as polyethylene glycol.
- a protein such as bovine serum albumin
- carrier such as polyethylene glycol.
- a spacer between the carrier and the probe may also be used.
- the polynucleotide comprising the probe may contain from about 15 to about 2,000 nucleotides. 0 Preferably, it contains from about 15 to about 200 nucleotides and most preferably from about 15 to about 40 nucleotides.
- the final step in this method of the invention is to detect or measure the presence of biotin in the bound as complex.
- a detectable moiety that binds to the biotin and then to detect such moiety.
- detectable moiety is comprised of a molecule or compound that binds to the biotin, such as avidin or streptavidin, ,0 coupled to a detectable entity (e.g., a detectable molecule or compound) , such as horseradish peroxidase.
- a detectable entity e.g., a detectable molecule or compound
- horseradish peroxidase is detected by known means.
- Other detectable moieties/detectable entities are disclosed in U.S. patent No. 4,711,955 " issued December 8, 1987 to Ward et al., which is incorporated herein by reference.
- the bound complexes are washed with a liquid, such as a buffer solution, before and/or after contact with the detectable moiety to remove any unbound, labeled sequences or labeled nucleoside triphosphates that may be present.
- a liquid such as a buffer solution
- the invention provides a method for a two-stage amplification of the signal provided by the biotin.
- the method may be used to detect target nucleic acid sequences that have been amplified through the formation of primer extension
- Such amplified sequences are rendered single- 20 stranded, and the sample containing such single-stranded sequences is contacted with immobilized probes as discussed above.
- the bound complexes comprising the single-stranded sequences and the single-stranded polynucleotides of the probes are then contacted with a first moiety that binds to 25 biotin.
- the moiety is preferably avidin or streptavidin.
- a second moiety, comprising biotin bound to a detectable moiety is then added to the sample.
- the biotin in the second moiety binds to the first moiety, which is bound to the biotin in the amplified sequences.
- the detectable SO moiety is then detected or measured by standard techniques.
- such detectable moiety is horseradish peroxidase.
- the solid support is washed between the steps discussed above in order to remove unbound materials that may interfere with the detection - procedure or give a false signal.
- the present invention also comprises a kit for detecting or measuring the presence of a target nucleic acid sequence in a sample suspected of containing that sequence.
- the kit comprises biotin-labeled nucleoside triphosphates and an appropriate primer pair.
- Each primer comprises an oligonucleotide having a region that is complementary to and hybridizes with a different strand of the target sequence and is effective as a primer for nucleoside polymerization.
- the kit further 5 comprises a probe that is complementary to and hybridizes with the target sequence.
- the kit further comprises a nucleic acid polymerase, preferably Tag polymerase, and additional means, such as reagents, for detecting or measuring the biotin, denaturing double- ⁇ stranded polynucleotides, and providing a control against which the results may be evaluated.
- a nucleic acid polymerase preferably Tag polymerase
- additional means such as reagents, for detecting or measuring the biotin, denaturing double- ⁇ stranded polynucleotides, and providing a control against which the results may be evaluated.
- the invention provides a kit for detecting or measuring the presence of a target nucleic acid sequence in HIV-l DNA in S a sample.
- the kit contains biotin-labeled nucleoside triphosphates, unlabeled nucleoside triphosphates, a primer pair comprising the nucleotide sequences:
- the object is a rapid and safe extraction of DNA to allow the processing of many samples.
- the suggested method is the following. Four hundred microliters (400 ul) of blood is collected in a tube
- • is containing anti-clotting agent (citrate or EDTA) and is contrifuged (e.g. 3,000 g for 5 minutes or 10,000 g for 5- 10 seconds) .
- the upper buffy-coat layer is removed, or the whole pellet is suspended in 200 ul distilled water in order to lyse the cells.
- the lysed cell suspension is ao boiled at 100*C in order to break up the cell nuclei.
- S buffer contains 0.3nmol of each primer (HOPE 1, HOPE 2), lOmM Tris-HCl, pH 8.4 (20 * C), 50mM KCl, 2mM MgCl 2 , 0.1% gelatin. 0.5mM dATP, dCTP, dGTP, 150 uM dTTP, 350 uM Bio- 11-dUTP, and 0.1% BSA (nuclease free). The reaction mix is incubated at 95*C for five minutes. This is to initially
- reaction buffer comprises lOOpmol each primer (melting temperature higher than 62*C, i.e.. NIDA1, NIDA2) , lOmM Tris-HCl, pH 8.0 (20*C), 1.8mM MgCl 2 , 50 mM KCl, 0.05% gelatin, O.lmM dATP, dCTP, dGTP, 03nM dTTP, 70nM Bio-11- dUTP, and 0.1% BSA (nuclease free).
- reaction mixture is then layered with one or two drops of any mineral oil and transferred to a programmable heat block where amplification takes place.
- the temperatures used are 90 * C for the initial and subsequent denaturation steps, and 70*C for annealing and elongation.
- the incubation period allowed for denaturation is one minute and for annealing, which is coupled with elongation, two minutes. This thermal profile is repeated 20 times, with the annealing-elongation step of the 20th cycle being the last step of the reaction.
- Reaction products are stored at 4 * C for further manipulation.
- the amplification reaction takes place in the wells of a 96- well ELISA plate, a very convenient way when dealing with a large number of samples.
- This type of reaction is essentially the same as the ACER, except for the amount of the primers, which now is 20pmol for HOPE 1 and 300pmol for HOPE 2.
- the volume of the DNA sample is also increased to 20 ul.
- the totality (100 ul) of the amplification reaction volume (ACER or CER) is applied to a well containing immobilized probe after heat denaturation (100 * C, five minutes) and snap cooling on ice. (Denaturation is not necessary when asymetric two temperatures, or one temperature reactions are performed.) Hybridization is allowed to proceed for one hour at 37 * C. Unbound material is removed by washing four times with 0.0M NaCl. A 50ng/ml solution of avidin-HRP in lOmM Tris-HCl pH 7.4 (20 ⁇ C), 5% gelatin, and 2% BSA is added to the well.
- the synthesis of the primers is standard and automated (Applied Biosystems synthesizer, model 380B) . Synthesis is based on a solid phase chemistry where the IS first base is already bound to a controlled pore glass
- CPG CPG support at the 3' end.
- the 5' end is protected with a dimethoxytrityl group.
- Each new base is covalently coupled to the previous base at the 5' end using a complete synthesis cycle.
- the cycle consists of 4 steps:
- the phosphorous of the new base is oxidized from the trivalent to the pentavalent form using a iodine-water-lutidine-tetrahydofuran mixture.
- the new base is accessible for the repeat of the cycle with the next base.
- elongation of the DNA chain is achieved with the correct nucleotide sequence.
- the product is cleaved from the CPG using 25% ammonia solution.
- the bases of the resultant oligonucleotide are then deprotected by heat- treatment at 55"C in the presence of ammonia for 5 hours.
- the product is evaporated to dryness to remove the ammonia, reconstituted in water and dried again, and finally reconstituted in water.
- the product is stored at -20*C until further use.
- the oligonucleotide H0PE4 (5' CTCTCTTTAA ACACCATGCT AACACAGT 3') (SEQ ID NO:6) was synthesized using a DNA synthesizer (Applied Biosystems) . It was then chemically coupled to bovine serum albumin, which was immobilized into ⁇ r the wells of a polystyrene microtiter plate according to the method of Running and Urdea, op. cit. r and Nagata, et al. , op. cit.
- DNA sample prepared from an infected culture of CEM cells. Several seronegative samples were also examined. A positive control-plasmid derived cloned sequences of HIV-I, and a negative control, were always included.
- HOPE 3 specific radiolabeled probe
- HOPE 2 acrylamide gel electrophoresis
- ADDRESSEE Dickstein, Shapiro &
Abstract
Disclosed herein are methods, primers, probes, and kits for the rapid amplification and detection of nucleic acids. In a preferred embodiment, a target nucleic acid sequence in a sample is amplified by: 1) adding nucleoside triphosphates, primer pairs comprising two oligonucleotide primers, and a nucleic acid polymerase to the sample; 2) denaturing the target nucleic acid sequence to form separate strands; and 3) maintaining a reaction temperature in a range from 68 °C to 80 °C and appropriate reaction conditions wherein the following cycle occurs: the primers hybridize to the target strands, primer extension products are formed, the extension products separate to become templates for the primers, and new extension products are formed. In an alternative embodiment, the amplification occurs at two different temperature ranges. Primer extension products are formed in a temperature range from 68 °C to 82 °C, and the products are separated by raising the temperature to range of 88 °C to 96 °C. Detection of the amplified sequences occurs by using some biotin-labeled nucleoside triphosphates, which produces nucleotide sequences that are copies of the target sequence and that contain one or more biotin-labeled nucleotides. The amplified sequences are detected by contacting the sample with immobilized probes and then detecting the presence of the biotin. A two-stage amplification process is also provided wherein: 1) the probe-target sequence complexes are contacted with a first moiety that binds to biotin; 2) a second moiety, comprising biotin bound to a detectable moiety is added, wherein the biotin in the second moiety binds to the first moiety; and 3) detecting or measuring the detectable moiety. In a particularly preferred embodiment, primer pairs and a probe are disclosed for use when the target nucleic acid is HIV-1 DNA.
Description
RAPID AMPLIFICATION AND DETECTION OF NUCLEIC ACIDS
FIELD OF THE INVENTION
This invention relates to the rapid amplification and detection of nucleic acids. In particular, the invention provides improved methods for amplifying small amounts of nucleic acids in a sample in which the
≤ amplifcation steps are conducted at the same temperature or, alternatively, at only two different temperatures. In addition, the invention provides improved methods for detecting the amplified nucleic acids in which the detection signal is boosted. Related probes and test kits
|0 are also provided. The invention is expected to be useful in a wide variety of fields, including scientific, clinical, and forensic analysis. In one specific embodiment, it is particularly useful in the detection of human immunodeficiency virus type 1 (HIV-1) , the causative
IS agent of AIDS.
BACKGROUND OF THE INVENTION
The ability to detect exceeding small amounts of a nucleic acid in a sample generally requires the amplification of the amount of the target nucleic acid. °LQ This is especially important for the detection of human retroviruses, where positive samples may contain only 5-10 target molecules in 106 cells.
The preferred method for amplifying target DNA has been the polymerase chain reaction (PCR) technique. The 2S technique has been described in U.S. Patent Nos. 4,683,195, issued July 28, 1987 to Mullis, et al., 4,683,202, issued
July 28, 1987 to Mullis, 4,800,159, issued January 24, 1989 to Mullis, et al., 4,889,818, issued December 26, 1989 to Gelfand, et al., and 4,902,624, issued February 20, 1990 to Columbus, et al., all of which are incorporated herein by S reference.
In general, the PCR reaction involves the use of a pair of specific oligonucleotide primers to initiate DNA synthesis on a target DNA template. Two oligonucleotide primers are used for each double-stranded sequence to be amplified. The target sequence is denatured into its complementary strands. Each of the primers, which are sufficiently complementary to a portion of each strand of the target sequence to hybridize with it, anneals to one of the strands. The primers are extended, using nucleosides S" in the sample and a polymerization agent, such as heat- stable Tag DNA polymerase. This results in the formation of complementary primer extension products, which are hybridized to the complementary strands of the target sequence. The primer extension products are then separated from the template strands, and the process is repeated until the desired level of amplification is obtained. In subsequent cycles, the primer extension products serve as new templates for synthesizing the desired nucleic acid sequence.
By repeating the cycles of denaturation, annealing, and extension, the original target DNA can be amplified exponentially according to the formula 2n, where n is the number of cycles. In theory, 25 cycles, for example, would result in a 3.4 x 107-fold amplification. However, since θ the efficiency of each cycle is less than 100%, the actual amplification after 25 cycles is about 1-3 x 106-fold. The
size of the amplified region is generally about 100-400 base pairs, although stretches of up to 2 kb can be amplified. See Keller and Manak, DNA Probes (New York: Stockton Press, 1989), pgs. 215-216.
-* The three basic steps of the PCR reaction — denaturation, annealing, and extension — are driven and controlled by the temperature of the reaction mixture, with each step occurring at a different temperature. Somewhat different temperature ranges are disclosed for each of the
10 three steps in the above-referenced patents. However, as time passed, those skilled in the art have settled on fairly standard temperatures for each of the steps in the cycle. Thus, Gelfand, et al., discloses a denaturing temperature range of about 90*-105'C, preferably 90*-100°C,
15 an annealing temperature range of about 35*-65'C, preferably 37*-60'C, and an extension temperature range of about 40*-80*C, preferably 50*-75*C. For Tag polymerase, which is the overwhelmingly preferred polymerase for the PCR reation, Gelfand, et al., refers to an annealing
20. temperature range of about 45*-58*C and an extension temperature range of about 65*-75*C. Columbus, et al., which is directed to a temperature cycling cuvette for use in PCR, refers to temperature ranges of 92*-95*C for the denaturing step, 50*-60*C for the annealing step, 70*C for s the extension step. Keller and Manak, cited above, refer to a denaturation temperature of about 93*C, an annealing temperature of 37*-55*C, and a primer extension temperature of 70*C.
The PCR technique has been modified to permit the 30 amplification of viral RNA. See Murakawa, et al., DNA, 7:287-295 (1988), which is incorporated herein by
reference. The article discloses the amplification of sequences from HIV-1 RNA templates for the identification of HIV-1 in peripheral blood and tissue samples obtained from AIDS and ARC patients. Total nucleic acid is isolated
S from infected cells, and the DNA is digested with RNase- free DNase so that it does not contribute to the final PCR product. A cDNA copy of a target sequence of the viral RNA is synthesized, using the PCR primers and reverse transcriptase. The one primer complementary to the RNA
10 serves to initiate cDNA synthesis.
Several different formats have been used for the detection of PCR products. Generally, a radioactive or nonradioactive labeled probe that is complementary to the target sequence is used. The hybridization of the probes 15 to the amplified target sequence, and the subsequent detection of the labeled moiety results in the detection of the target sequence. Nonradioactive labeled probes are generally more desirable because they obviate the need for special handling procedures. However, they may not ao generate as intense a signal, or the signal may be obscurred by background "noise." Thus, there is a need for enhancing the intensity of the signal in such probes.
The PCR technique is a revolutionary one, and it is widely used. Nevertheless, it does have significant 5 drawbacks. The most serious of these is nonspecific hybridization, which results in false positives. Avoiding nonspecific hybridization requires ultrapure reagents. Unfortunately, for most clinical and diagnostic applications, it is desirable to use "dirty" samples, which
*_0 presents a major problem, unless time-consuming and expensive sample preparation is undertaken.
Another important drawback to the PCR technique is the time involved in amplification. Although the usual six hour time period for PCR is far superior to an alternative technique such as cloning, which can take days or weeks, it 5" would still be desirable to cut amplification time by one- half to two-thirds.
The present invention overcomes these drawbacks of the PCR technique, and it provides an improved detection system. The invention provides methods for the rapid
10 amplification and detection of nucleic acids in which the ' denaturing, annealing, and extension steps occur all at the same temperature or, alternatively, at only two different temperatures, thus providing for faster cycling. In addition, the invention provides amplification methods
IS where the annealing temperature is higher than the prior art temperatures, thus eliminating nonspecific hybridization. Finally, the invention provides improved methods of detecting the amplified nucleic acids through a two-stage signal amplification.
■aO SUMMARY OF THE INVENTION
It is an object of the present invention to provide methods for amplifying a target nucleic acid sequence in a sample.
Another object is to provide methods for detecting I or measuring the presence of a target nucleic acid sequence in a sample.
Still another object of the invention is to provide a kit for detecting or measuring the presence of a target nucleic acid sequence in a sample.
A further object of the invention is to provide 5 primer pairs for use in amplifying a nucleic acid sequence of HIV-1 DNA.
A still further object is to provide a probe for use in detecting a nucleotide sequence complementary to a target nucleic acid sequence of HIV-l DNA.
•0 Additional objects and advantages of the invention will be set forth in part in the description that follows, and in part will be obvious from the description, or may be learned by the practice of the invention. The objects and advantages of the invention will be attained by means of
I the instrumentalities and combinations particulary pointed out in the appended claims.
To achieve the objects and in accordance with the purpose of the invention, as embodied and broadly described herein, the present invention provides a method for ao amplifying a target nucleic acid sequence in a sample. The sequence is part of a nucleic acid, which the sample is suspected of containing. Preferably, the target nucleic acid is DNA, most preferably HIV-l DNA.
Nucleoside triphosphates, primer pairs consisting (jS of two oligonucleotide primers, and a nucleic acid polymerase are added to the sample. Each primer is an oligonucleotide having a region that is complementary to and hybridizes with a different strand of the target
sequence. It is effective as an initiator for nucleoside polymerization. If double stranded, the nucleic acid in the sample is denatured so that separate strands of the target nucleic acid sequence are formed. Preferably, the S denaturing is accomplished by heating the sample to about 95βC.
A reaction temperature in a range from about 68βC to about 80°C (preferably about 75*C) and appropriate reaction conditions are maintained so that the following 0 cycle occurs. First, the primers anneal (hybridize) to the separate strands of the target sequence. The primers and the nucleic acid polymerase initate the synthesis of primer extension products, formed by the nucleosides attaching to the primer and forming a polymer, using the target sequence
IS strand as a template. Thus, the primer extension products are annealed or hybridized to the strands. The primer extension products are then separated from the strands to become templates for the primers, and the cycle is repeated, with new primer extension products being formed.
_lθ The reaction is allowed to continue for a sufficient number of cycles until the desired amplification of the target nucleic acid sequence has been accomplished. The primers are chosen so that they bind strongly to the strands of the target sequence, but the extension from each primer binds as weakly to the strand.
In an alternative embodiment of the invention, the cycling occurs at two different temperatures. The reaction temperature is maintained in a range from about 68*C to about 82*C (preferably about 70*C) and appropriate reaction 3 conditions are maintained to form the primer extension products. These are separated from the strands by raising
the temperature to a range of about 88*C to about 96*C (preferably about 90*C) to produce single-stranded molecules. The temperature is then lowered back to the previously mentioned range, permitting the primers to S anneal to the single-stranded molecules and primer extension products to be synthesized, using the single- stranded molecules as templates. The temperature cycling is repeated a sufficient number of times to obtain the desired amplification of the target nucleic acid sequence.
0 The invention also provides methods for detecting or measuring a target nucleic acid sequence in a sample, based upon the amplification methods discussed above. In these methods, some of the nucleoside triphosphates are biotin-labeled. This produces nucleotide sequences that
\£ are copies of the target sequence which contain one or more biotin-labeled nucleotides. Such sequences are rendered single-stranded and contacted with immobilized probes. Each of the probes is a single-stranded polynucleotide attached to a solid support and capable of hybridizing with
HO one of the single-stranded nucleotide sequences. The probes are contacted with the sample for a sufficient time and under appropriate hybridizing conditions to permit the polynucleotides to hybridize with the single-stranded nucleotide sequences. This forms bound complexes comprised a of both of these entities. The presence of the biotin in the bound complexes is then detected or measured. Preferably, the biotin is detected by contacting the bound complexes with a detectable moiety that binds to biotin, such as avidin-horseradish peroxidase, and then detecting
30 the detectable moiety, i.e., the horseradish peroxidase.
In an alternative and prefered embodiment, the detecting step is accomplished by contacting the bound complexes with a first moiety that binds to biotin, such as avidin. A second moiety, comprising biotin bound to $ detectable moity, such as horseradish peroxidase, is then added. The biotin in this second moiety binds to the first moiety. The detectable moiety is then detected. This provides a two-stage amplification of the signal.
The invention further provides kits for detecting \ϋ or measuring the presence of a target nucleic acid sequence in a sample. The kits contain biotin-labeled nucleoside triphosphates and a primer pair specific for the particular target sequence sought to be detected or measured. Preferably, the kit further comprises a probe that is \S specific for the target sequence. It may also contain a nucleic acid polymerase, reagents for detecting or measuring the biotin, denaturing reagents, and/or controls.
In a preferred embodiment of the kit, the target nucleic acid sequence is HIV-l DNA. The primer pair ao comprises the nucleotide sequences
5' GAAGGAGCCA CCCCACAAG 3' (SEQ ID NO: 1)
3' CCCCCCTGTA GTTCGTCGG 5' (SEQ ID NO: 2)
and the probe comprises the nucleotide sequence
5' TTTAAACACC ATGCTAAACA CAGT 3'. (SEQ ID NO: 3)
DETAILED DESCRIPTION OF THE INVENTION
Reference will now made in detailed to the presently preferred embodiments of the invention which, together with the following examples, serve to explain the principles of the invention.
The invention provides improved methods for amplifying and detecting nucleic acids. The target nucleic acid may be single or double-stranded DNA or RNA from any organism. Such organisms include plants, animals, and microorganisms, such viruses, viroids, mycoplasma, bacteria, and fungi. The viruses include DNA and RNA viruses. In a preferred embodiment, the viruses are retroviruses, and in a particularly preferred embodiment, they are the AIDS-related viruses (including HIV-l and HIV- 2) . The term "animals" includes mammals, and, in a preferred embodiment, the target nucleic acid is mammalian nucleic acid, such as mitochondrial or genomic DNA or the various types of RNA. Such nucleic acid further includes human cellular oncogene sequences and human structural gene sequences.
The sample may be anything that contains nucleic acid, obtained from a source by techniques known to those skilled in the art. It may be further processed by known techniques, such as being subjected to extraction procedures, to render it in a form usable in the method of the invention. For example, the method of the present invention can be applied to determine if a patient has been infected by a virus. A sample of body fluid or tissue that contains the virus is obtained from the patient. In this case, the sample should contain cells that are capable of
being infected by the virus or should contain body fluid in which the virus or viral nucleic acid is known to accumulate. The viral nucleic acid is extracted from the sample by known techniques.
A target nucleotide sequence within the target nucleic acid is selected so as to provide a target of sufficient specificity and uniqueness in order to be identified and distinguished from other nucleic acid molecules in the sample. Among other things, it will be selected on the basis of a nucleotide base sequence specific to the organism. For many viruses, in particular those that mutate at high rates, it is advisable to select a target sequence from a well-conserved region of the viral genome.
The target nucleotide sequence may consist of from about 50 to about 4000 base pairs, but preferably consists of about 55 to about 200 base pairs, and most preferably consists of about 60 to about 100 base pairs. In the case of HIV-l DNA, the preferred target sequences are the c nucleotide sequence 1317-1379 of pHXB2 and 331-530 of pHXB2, depending upon which primer pair of the invention is used to amplify the sequence.
In the preferred embodiment of the invention, the target sequence is amplified in a reaction that occurs at a single temperature, after the initial denaturation of the nucleic acid, in contrast to the three different temperatures in the PCR technique. We call this method the Continuous Enzyme Reaction (CER) . In the first step, certain reagents are added to the sample that contains the o target nucleic acid. In particular, nucleoside
triphosphates, including biotinylated nucleotide triphosphates, primer pairs, and a nucleic acid polymerase are added. Preferably, they are added as part of a buffered solution. Each primer is an oligonucleotide having a region that is complementary to and hybridizes with a different strand of the target sequence. It is effective as an initiator for nucleoside polymerization. Preferably, the length of each primer is approximately 15- 25 nucleotides.
The target nucleic sequence, if it is double- stranded, is then separated into single strands by known techniques. Preferably, the nucleic acid is denatured by heating the sample to about 95*C. The target sequence may be denatured before the other reagents are added to the sample, although it is preferable to denature it afterwards.
The sample is then maintained under appropriate reaction conditions to permit the following cycle to occur: (1) each of the oligonucleotide primers anneals (hybridizes) to each of the strands of the denatured target sequence; (2) primer extension products are synthesized from the nucleoside triphosphates, with the systhesis being initiated by the primer and catalyzed by the nucleic acid polymerase; and (3) a portion of the extension products, which are hybridized to the strands of the target sequence, separate spontaneously from the strands. The separated extension products become templates for the primers, and the cycle is repeated. Such reaction conditions include maintaining the reaction temperature somewhere in the range from about 68*C to about 80*C. Preferably, the temperature is maintained at about 75*C.
The reaction is permitted to proceed for a sufficient period of i e so that the cycle is repeated about 10 to about 25 cimes. This will occur over a time ranging from about 1.0 hours to about 2.5 hours. 5 Generally, the longer reaction time is preferred.
The nucleoside triphosphates are readily available commercially or can be synthesized by those skilled in the art. When the method of the invention is applied to the amplification of DNA, deoxyribonucleoside triphosphates are \o used.
Most preferably, some of the nucleoside triphosphates or deoxyribonucleoside triphosphates are labeled with biotin. This permits the incorporation of a reporter molecule into the amplified sequences, which can
Ig- be detected by the means described below. Such biotin- labeled nucleoside triphosphates can be synthesized by known techniques or are commercially available. The preferred biotin-labeled nucleoside triphosphate is Bio- dUTP. The labeled nucleosides are used in a concentration of about 10 uM to about 5mM, and preferably from about 0.1 mM to about 0.5 mM.
The polymerizing agent is any polymerase for nucleic acid. Preferably, it is Tag polymerase, which is heat stable under these reaction conditions.
o_^ The primer pairs consist of two oligonucleotide primers. Each primer is an oligonucleotide having a region that is complementary to and hybridizes with a different strand of the target sequence, and is effective as an
initiator (primer) for nucleoside polymerization. The primers of the invention are selected so as to meet two requirements. First, they must bind strongly to the strands of the target sequence to allow binding at a
S temperature higher than the temperature preferred in the literature. Second, the product from the extension of the primers, which is synthesized from the nucleosides in the presence of the polymerase, is the least stable of a series of products which were initially selected and more likely
10 to dissociate spontaneously to single-stranded form, thus itself becoming a target sequence of the appropriate primer. As used herein, the term "bind strongly" and variations thereof means adequately stable single-stranded 16DNA-primer hybrids are formed at the high temperature of
IS the invention.
This is accomplished by choosing primers where the ratio of G and C to A and T in the primers ranges from about 1.5:1 to about 3.0:1. Preferably, the ratio is about 3.0:1. This is confirmed by the temperature of Q dissociation (Td) of the primer pair and the melting temperature (Tm) of the extension products. The Td of the primer pair is calculated from the formula Td = 4"(C+G) + 2"(A+T). The Tm, which is the temperature at which the extension products are denatured, is calculated from the 5" formula:
Tm = 81.5° + 16.6 log Ci + 0.41 (% C+G) - 0.72 (% forma ide) - 82°/n - 1.5 (% mismatch)
where Ci is the ionic strength of the reaction solution and n is the number of nucleotides.
For HIV-l DNA, the following specific primers, which we call HOPE 1 and HOPE 2, are preferred:
HOPE 1: 5' GAAGGAGCCA CCCCACAAG 3' (SEQ ID NO: 1)
HOPE 2: 3' CCCCCCTGTA GTTCGTCGG 5' (SEQ ID NO: 2)
s These primers produce HIV-l DNA sequences in positions 1317-1379 of the plasmid pHXB2, which are 63 base pairs long. The Td for HOPE 1 is 62*C and that for HOPE 2 is 64*C. The Tm of the product, i.e., the primer extension, is 76.7'C.
o The use of primers meeting the above-stated conditions permits the maintenance of temperature and other reaction conditions whereby the amplification cycle occurs at a single temperature rather than three different temperatures. In order for the reaction to occur
S≤ efficiently in terms of yielding double-stranded target DNA, the following reaction conditions should be considered:
1) The temperature should be high enough so that a substantial portion of the target DNA is found in single-
3θ stranded form, available for primer hybridization (the activity of the polymerase is a limiting factor) .
2) The concentration of the primers should be high enough so as to favor single-stranded DNA-primer hybrid formation.
3) The GC content of the primers should be such as to allow an adequately stable single-stranded DNA-primer hybrid to be formed at the high temperature chosen.
4) The primer extension product, on the contrary, should be as unstable as possible so that the probability for the two strands to dissociate spontaneously is as high as possible.
5) The polymerizing agent should be able to efficiently polymerize dNTPs at the high temperature chosen and also to incorporate the dNTP analogue used as a label onto DNA strands.
Generally, the cycle of primer annealing, primer extension, and extension product denaturing occurs from about 10 to about 25 times. The time period for this to occur is approximately 0.5 hours to overnight.
In an alternative and preferred embodiment, asymmetric concentrations of the primers are used. That is, the concentration of one of the primers exceeds that of the other by a factor of about 103 to 1, and preferably by c about 102 to about 1. This permits the build up of only one instead of two primer extension products. Therefore, there is only a limited risk of DNA-DNA co plexing during hybridization. Instead, the product DNA will bind to the primer or the probe that is used for detection of the S" amplified DNA. This enhances both the specificity and sensitivity of the assay.
When the nucleic acid to be amplified is RNA, certain modifications are made. The RNA template in infected cells is either viral RNA or packaged virion RNA. Total nucleic acid is isolated in crude form by known
5 methods, or it can be purified by, for example, phenol- chloroform extraction. Residual DNA may be digested with RNase-free DNase so that it does not contribute to the amplified sequences. A cDNA copy of a target ribonucleotide sequence in the target RNA is synthesized, lo using the primers and reverse transcriptase. The primer complementary to the target sequence serves to initate cDNA synthesis. The single-stranded cDNA product can be amplified after heat inactivation of the reverse transcriptase and adjustment of the reaction conditions to
IS those of the method of the invention.
In an alternative embodiment of the invention, the amplification of the target nucleic acid sequence occurs at two different temperatures. The primer annealing and extension steps occur at one temperature, and the Sfø denaturing of the primer extension products occurs at another temperature. We call this method the Accelerated Chain Enzyme Reaction (ACER) .
In particular, the reaction temperature is maintained at a point in the range from about 68*C to about 82*C for primer annealing and extension. Preferably, the reaction temperature for these steps of the cycle is about 70*C. The primer extension products are separated from the target sequence strands or other extension products by raising the temperature to a range of about 88*C to about 0 96*C. This denatures the extension products from the template, producing single-stranded molecules that serve as
further templates when the temperature is lowered. Preferably, the denaturing step occurs at a temperature of about 90•C.
The cycling between these two temperatures is repeated about 10 to about 25 times. The reaction time for these steps is from about 0.5 hours to about 3 hours. Generally, the time is about 1.5 hours.
The preparation of the sample and the initial reaction mixture is essentially the same as in the single temperature method. The target nucleic acid sequence is also denatured in the same manner. This method also lends itself to the use of asymmetric concentrations of primers and to the amplification of RNA as discussed previously.
The specific primers for any given target sequence are determined as discussed above with respect to the single temperature embodiment. The primers will have the same general characteristics mentioned above. For HIV-l DNA, the previously mentioned HOPE 1 and HOPE 2 primers are preferred. In addition, two other primers, which we designate NIDA 1 and NIDA 2, are preferred. These primers comprise the following sequences:
NIDA 1: 5' GACATCGAGC TTGCTAGAAG 3' (SEQ ID NO: 4)
NIDA 2: 3' GGTGACGAAT TCGGAGTTAT 5' (SEQ ID NO: 5)
They produce HIV-l DNA sequences in positions 331-530 pHXB2.
In another embodiment, the invention comprises a method for detecting or measuring a target nucleic acid in a sample. The target sequence is amplified according to the methods discussed above, wherein some of the nucleoside triphosphates are biotin-labeled. This produces nucleotide sequences that are copies of the target sequence and contain one or more biotin-labeled nucleotides. The amplified sequences, which will be double-stranded, are then rendered single-stranded by known techniques, preferably heat denaturation at a temperature of about 88*C to about 96*C. The sample is then contacted with immobilized probes. These probes are single-stranded polynucleotides attached to a solid support. Each one is capable of hybridizing with one of the single-stranded nucleotide sequences. The probes are contacted with the sample for a sufficient time and under appropriate hybridizing conditions known to those skilled in the art to permit the polynucleotides to hybridize with the single- stranded nucleotide sequences. This forms bound complexes of the polynucleotides and the single-stranded nucleotide sequences.
The probes can be prepared by standard techniques known to those skilled in the art, given the particular target sequence and the teachings contained herein. When the nucleic acid is HIV-l DNA, the preferred probe comprises the sequence 5' TTTAAACACC ATGCTAAACA CAGT 3' (SEQ ID NO: 3), which we call the HOPE 3 probe. The HOPE 3 probe may also be used with a pyri idine spacer at the 5'end. Preferably, the spacer is CTCTC, in which case we call the probe HOPE 4.
The solid support may be any solid material to which the probe may be attached. Such material includes filters, resins, beads, cubes, and microtiter plates. Preferably, the solid supports are the wells in plastic 5 microtiter plates, such as polystyrene microtiter plates. Most preferably, the probe is first chemically coupled to a protein carrier, such as bovine serum albumin, which is then immobilized onto polystyrene microtiter plate wells. See Running and Urdea, BioTechniques. 8:276-277 (1990) and \0 Nagata, et al., FEBS Letters. 183:379-382 (1985), both of which are incorporated herein by reference.
The single-stranded polynucleotide of the probe is attached to the solid support covalently or noncovalently by means known to those skilled in the art. Preferably,
IS the probe is chemically coupled to a protein, such as bovine serum albumin, or other carrier, such as polyethylene glycol. A spacer between the carrier and the probe may also be used. The polynucleotide comprising the probe may contain from about 15 to about 2,000 nucleotides. 0 Preferably, it contains from about 15 to about 200 nucleotides and most preferably from about 15 to about 40 nucleotides.
The final step in this method of the invention is to detect or measure the presence of biotin in the bound as complex. One way of doing so is to contact the bound complexes with a detectable moiety that binds to the biotin and then to detect such moiety. Preferably, such detectable moiety is comprised of a molecule or compound that binds to the biotin, such as avidin or streptavidin, ,0 coupled to a detectable entity (e.g., a detectable molecule or compound) , such as horseradish peroxidase. The
horseradish peroxidase is detected by known means. Other detectable moieties/detectable entities are disclosed in U.S. patent No. 4,711,955"issued December 8, 1987 to Ward et al., which is incorporated herein by reference.
S Preferably, the bound complexes are washed with a liquid, such as a buffer solution, before and/or after contact with the detectable moiety to remove any unbound, labeled sequences or labeled nucleoside triphosphates that may be present.
IC In a particulary preferred embodiment, the invention provides a method for a two-stage amplification of the signal provided by the biotin. The method may be used to detect target nucleic acid sequences that have been amplified through the formation of primer extension
IS products that contain one or more biotin-labeled nucleotides. Thus, it is particularly applicable to the amplification methods of the present invention, but it is not limited to them.
Such amplified sequences are rendered single- 20 stranded, and the sample containing such single-stranded sequences is contacted with immobilized probes as discussed above. The bound complexes comprising the single-stranded sequences and the single-stranded polynucleotides of the probes are then contacted with a first moiety that binds to 25 biotin. The moiety is preferably avidin or streptavidin. A second moiety, comprising biotin bound to a detectable moiety, is then added to the sample. The biotin in the second moiety binds to the first moiety, which is bound to the biotin in the amplified sequences. The detectable SO moiety is then detected or measured by standard techniques.
Preferably, such detectable moiety is horseradish peroxidase. Preferably, the solid support is washed between the steps discussed above in order to remove unbound materials that may interfere with the detection - procedure or give a false signal.
The present invention also comprises a kit for detecting or measuring the presence of a target nucleic acid sequence in a sample suspected of containing that sequence. The kit comprises biotin-labeled nucleoside triphosphates and an appropriate primer pair. Each primer comprises an oligonucleotide having a region that is complementary to and hybridizes with a different strand of the target sequence and is effective as a primer for nucleoside polymerization. Preferably, the kit further 5 comprises a probe that is complementary to and hybridizes with the target sequence. Most preferably, the kit further comprises a nucleic acid polymerase, preferably Tag polymerase, and additional means, such as reagents, for detecting or measuring the biotin, denaturing double- θ stranded polynucleotides, and providing a control against which the results may be evaluated.
In a particularly preferred embodiment, the invention provides a kit for detecting or measuring the presence of a target nucleic acid sequence in HIV-l DNA in S a sample. The kit contains biotin-labeled nucleoside triphosphates, unlabeled nucleoside triphosphates, a primer pair comprising the nucleotide sequences:
5' GAAGGAGCCA CCCCACAAG 3' (SEQ ID NO: 1)
3' CCCCCCTGTA GTTCGTCGG 5' (SEQ ID NO: 2)
and a probe comprising the nucleotide sequence
5' TTTAAACACC ATGCTAAACA CAGT 3'. (SEQ ID NO: 3)
It is to be understood that the application of the teachings of the present invention to a specific problem or environment will be within the capabilities of one having ordinary skill in the art in light of the teachings contained herein. Examples of the products and processes of the present invention appear in the following examples.
EXAMPLE 1
to Isolation of DNA From Blood
For AIDS screening, the object is a rapid and safe extraction of DNA to allow the processing of many samples. The suggested method is the following. Four hundred microliters (400 ul) of blood is collected in a tube
• is containing anti-clotting agent (citrate or EDTA) and is contrifuged (e.g. 3,000 g for 5 minutes or 10,000 g for 5- 10 seconds) . The upper buffy-coat layer is removed, or the whole pellet is suspended in 200 ul distilled water in order to lyse the cells. The lysed cell suspension is ao boiled at 100*C in order to break up the cell nuclei.
Centrifugation for 5 minutes at 10,000 g removes insoluble debris. The resultant supernatant is used for subsequent manipulations.
_ EXAMPLE 2
One Temperature Reaction (CER)
Fifteen ul of DNA sample prepared as in Example 1 are added to 80 ul of a reaction buffer. The reaction
S buffer contains 0.3nmol of each primer (HOPE 1, HOPE 2), lOmM Tris-HCl, pH 8.4 (20*C), 50mM KCl, 2mM MgCl2, 0.1% gelatin. 0.5mM dATP, dCTP, dGTP, 150 uM dTTP, 350 uM Bio- 11-dUTP, and 0.1% BSA (nuclease free). The reaction mix is incubated at 95*C for five minutes. This is to initially
\0 denature the DNA. The mix is then allowed to cool down to room temperature, three units of the enzyme Vent polymerase (New England Biolabs) are added, and mineral oil is layered at the top. The reaction then takes place at 78*C for 3-4 hours.
IS EXAMPLE 3
Two Temperature Reaction (ACER)
Ten microliters of the DNA containing supernatant prepared as in Example 1 are used for this amplification reaction. This volume is mixed with 90 ul of reaction ac< buffer. The reaction buffer comprises lOOpmol each primer (melting temperature higher than 62*C, i.e.. NIDA1, NIDA2) , lOmM Tris-HCl, pH 8.0 (20*C), 1.8mM MgCl2, 50 mM KCl, 0.05% gelatin, O.lmM dATP, dCTP, dGTP, 03nM dTTP, 70nM Bio-11- dUTP, and 0.1% BSA (nuclease free).
•I The reaction mixture is then layered with one or two drops of any mineral oil and transferred to a programmable heat block where amplification takes place.
The temperatures used are 90*C for the initial and subsequent denaturation steps, and 70*C for annealing and elongation. The incubation period allowed for denaturation is one minute and for annealing, which is coupled with elongation, two minutes. This thermal profile is repeated 20 times, with the annealing-elongation step of the 20th cycle being the last step of the reaction. Reaction products are stored at 4*C for further manipulation. The amplification reaction takes place in the wells of a 96- well ELISA plate, a very convenient way when dealing with a large number of samples.
EXAMPLE 4
Two Temperature Asymmetric Reaction (AACER)
This type of reaction is essentially the same as the ACER, except for the amount of the primers, which now is 20pmol for HOPE 1 and 300pmol for HOPE 2. The volume of the DNA sample is also increased to 20 ul.
EXAMPLE 5
Detection of Amplified Products
The totality (100 ul) of the amplification reaction volume (ACER or CER) is applied to a well containing immobilized probe after heat denaturation (100*C, five minutes) and snap cooling on ice. (Denaturation is not necessary when asymetric two temperatures, or one temperature reactions are performed.) Hybridization is allowed to proceed for one hour at 37*C. Unbound material is removed by washing four times with 0.0M NaCl.
A 50ng/ml solution of avidin-HRP in lOmM Tris-HCl pH 7.4 (20βC), 5% gelatin, and 2% BSA is added to the well. After incubating 30 minutes at room temperature with shaking, the well is washed with 0.9M NaCl, lOmM Tris-HCl, pH 7.4 (20*C), and 0.1% Tween-20. The substrate mix is then applied (0.05% TetraMethylBenzidine, 10% H2O2) . Blue color develops within 10 minutes. The colorigenic reaction is stopped with 0.5% H2SO4, and absorbence at 450nm is measured.
0 EXAMPLE 6
Preparation of the Primers
The synthesis of the primers is standard and automated (Applied Biosystems synthesizer, model 380B) . Synthesis is based on a solid phase chemistry where the IS first base is already bound to a controlled pore glass
(CPG) support at the 3' end. The 5' end is protected with a dimethoxytrityl group. Each new base is covalently coupled to the previous base at the 5' end using a complete synthesis cycle. The cycle consists of 4 steps:
_tO 1. Detritylation. The attached (terminal) base is detritylated with trichloroacetic acid creating a free hydroxyl group.
2. Activation and addition. The next base is activated with tetrazole at the 3' end and then is passed S through the CPG column allowing it to react with 5' hydroxyl of the terminal base.
3. Capping. The unreacted 5' hydroxyl groups (approximately 0-2%) are blocked with acetic anhydride (acetylation) .
4. Oxidation. The phosphorous of the new base is oxidized from the trivalent to the pentavalent form using a iodine-water-lutidine-tetrahydofuran mixture.
After the completion of the synthesis cycle, the new base is accessible for the repeat of the cycle with the next base. Thus, elongation of the DNA chain is achieved with the correct nucleotide sequence.
At the end of the run, the product is cleaved from the CPG using 25% ammonia solution. The bases of the resultant oligonucleotide are then deprotected by heat- treatment at 55"C in the presence of ammonia for 5 hours.
The product is evaporated to dryness to remove the ammonia, reconstituted in water and dried again, and finally reconstituted in water. The product is stored at -20*C until further use.
EXAMPLE 7
0 Preparation of the Probe
The oligonucleotide H0PE4 (5' CTCTCTTTAA ACACCATGCT AACACAGT 3') (SEQ ID NO:6) was synthesized using a DNA synthesizer (Applied Biosystems) . It was then chemically coupled to bovine serum albumin, which was immobilized into ≤r the wells of a polystyrene microtiter plate according to
the method of Running and Urdea, op. cit. r and Nagata, et al. , op. cit.
EXAMPLE 8
Evaluation of Samples
Eight seropositive samples were examined, plus a
DNA sample prepared from an infected culture of CEM cells. Several seronegative samples were also examined. A positive control-plasmid derived cloned sequences of HIV-I, and a negative control, were always included.
Some samples were analyzed by applying CER and others by ACER. Amplification products were detected by either in solution hybridization with a specific radiolabeled probe (HOPE 3) and subsequent acrylamide gel electrophoresis or the ELISA-like colorimetric assay using as label a biotinylated dNTP analog or a labeled primer (HOPE 2) .
The values obtained were as follows:
Absorbance readings of ELISA-like assay:
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANTS: Nectarios Tavernarakis,
George Hatzidakis, and ^ Elias Krambovitis
(ii) TITLE OF INVENTION: RAPID AMPLIFICATION
AND DETECTION OF NUCLEIC ACIDS
(iϋ) NUMBER OF SEQUENCES: 5
*0 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Dickstein, Shapiro &
Morin
(B) STREET: 2101 L Street, N.W.
(C) CITϊ: Washington
(D) STATE: D.C.
\S (E) COUNTRY: U.S.A.
(F) ZIP: 20037
(V) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
^O (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII
(Vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
S (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Karny, Geoffrey M. \ C (B) REGISTRATION NUMBER: 31,382
(C) DOCKET NUMBER: 12277.001/POOl
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (202) 785-9700
(B) TELEFAX: (202) 887-0689
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:
GAAGGAGCCA CCCCACAAG 19
(3) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 nucleotides
(B) TYPE: nucleic acid
^ (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(Xi) SEQUENCE DESCRIPTION; SEQ ID NO:2:
CCCCCCTGTA GTTCGTCGG 19
\C (4) INFORMATION FOR SEQ ID NO:3:
«
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single IS (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
TTTAAACACC ATGCTAAACA CAGT 24
(5) INFORMATION FOR SEQ ID NO:4:
^O (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
GACATCGAGC TTGCTAGAAG 20
(6) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
GGTGACGAAT TCGGAGTTAT 20
(7) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
( ii ) MOLECULE TYPE : DNA
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
CTCTCTTTAA ACACCATGCT AACACAGT 28
Claims
1. A method for amplifying a target nucleic acid sequence in a sample, wherein said target sequence consists of two complementary strands, comprising the steps of:
(a) adding nucleoside triphosphates, primer pairs comprising two oligonucleotide primers, and a nucleic acid polymerase to said sample;
(b) denaturing said target nucleic acid sequence to form separate strands; and
(c) maintaining a reaction temperature in a range from about 68"C to about 80*C and appropriate reaction conditions wherein the following cycle occurs: said primers hybridize to said strands of said target sequence, primer extension products, which are hybridized to said strands, are formed from said primers and said nucleoside triphosphates, said extension products separate from said strands to become templates for said primers, and new primer extension products are formed.
2. The method of claim 1 wherein said target sequence is denatured by heating said sample to about 95*C.
3* The method of claim 1 wherein the reaction temperature in step (c) is maintained at about 75*C.
4. The method of claim 1 wherein said primers bind strongly to the strands of said target sequence and the extensions from said primers bind weakly to the strands of said target sequence.
5. The method of claim 4 wherein the ratio of G and C to A and T in said primers ranges from about 1.
5:1 to about 3.0:1.
6. The method of claim 5 wherein said ratio is S about 3.0:1.
7. The method of claim 5 wherein the length of said primers is about 15-25 nucleotides.
8. The method of claim 5 wherein the concentration of one of said primers in said primer pair
10 exceeds the concentration of the other primer by a factor of about 103 to 1 to about 102 to 1.
9. The method of claim 1 wherein the cycle of step (c) is repeated about 10 to about 25 times.
10. The method of claim 1 wherein the reaction
IS temperature and conditions of step (c) are maintained for a time from about 1.0 hours to about 2.5 hours.
11. The method of claim 1 wherein said nucleic acid is AIDS-related viral nucleic acid.
12. The method of claim 1 wherein said target aθ nucleic acid is RNA and said sample is treated with reverse transcriptase.
13. The method of claim 1 wherein said target nucleic acid is DNA and said nucleoside triphosphates are deoxynucleoside triphosphates.
14. The method of claim 13 wherein said DNA is HIV-l DNA.
15. The method of claim 14 wherein said target sequence is the nucleotide sequence 1317-1379 of pHXB2.
S~
16. The method of claim 15 wherein said primer pair comprises the nucleotide sequences
5' GAAGGAGCCA CCCCACAAG 3' (SEQ ID NO: 1)
3' CCCCCCTGTA GTTCGTCGG 5'. (SEQ ID NO: 2)
17. A method for detecting or measuring a target 10 nucleic acid sequence in a sample, wherein said target sequence consists of two complementary strands, comprising the steps of:
(a) amplifying said target sequence according to claim 1, wherein some of said nucleoside triphosphates
IS are biotin-labeled, thereby producing nucleotide sequences that are copies of said target nucleotide sequence and contain one or more biotin-labeled nucleotides;
(b) rendering said nucleotide sequences single-stranded;
SO (c) contacting said sample containing said single-stranded nucleotide sequences with immobilized probes, each of which comprises a single-stranded polynucleotide attached to a solid support and capable of hybridizing with one of said single-stranded nucleotide
sequences, for a sufficient time and under appropriate hybridizing conditions to permit said polynucleotides to hybridize with said single-stranded nucleotide sequences, thereby forming bound complexes of said polynucleotides and g- said single-stranded nucleotide sequences; and
(d) detecting or measuring the presence of biotin in said bound complexes.
18. The method of claim 17 wherein said solid support is a microtiter plate.
0 19. The method of claim 17 wherein said detecting or measuring step comprises the steps of:
contacting said bound complexes with a detectable moiety that binds to biotin; and
detecting or measuring said detectable moiety.
S 20. The method of claim 19 wherein said detectable moiety is avidin-horseradish peroxidase.
21. The method of claim 17 wherein said detecting or measuring step comprises the steps of:
contacting said bound complexes with a first C moiety that binds to biotin;
adding a second moiety comprising biotin bound to a detectable moiety, whereby the biotin in said second moiety binds to said first moiety; and
detecting or measuring said detectable moiety.
22. The method of claim 21 wherein said first moiety is avidin and said detectable moiety is horseradish peroxidase.
23. The method of claim 19 wherein said nucleic acid is HIV-l DNA and said single-stranded polynucleotide of said probe comprises the sequence
5' TTTAAACACC ATGCTAAACA CAGT 3' (SEQ ID NO: 3) or
5' CTCTCTTTAA ACACCATGCT AACACAGT 3' (SEQ ID NO: 6).
10 24. A method for amplifying a target nucleic acid sequence in a sample, wherein said target sequence consists of two complementary strands, comprising the steps of:
(a) adding nucleoside triphosphates, primer pairs comprising two oligonucleotide primers, and a nucleic S acid polymerase to said sample;
(b) denaturing said target nucleic acid sequence to form separate strands;
(c) maintaining the reaction temperature in a range from about 68*C to about 82*C and appropriate
3.C reaction conditions to form primer extension products from said primers and said nucleoside triphosphates, wherein said extension products are hybridized to said strands;
(d) separating said extension products from said strands by raising the temperature to a range of about 88*C to about 96*C to produce single-stranded molecules;
(e) lowering the reaction temperature to a 5" range from about 68*C to about 82*C and maintaining appropriate reaction conditions to synthesize primer extension products from said primers and said nucleoside triphosphates using the single-stranded molecules produced by step (d) as a template; and
l° (f) repeating steps (d) and (e) a sufficient number of times to obtain the desired amplification of said target nucleic acid sequence.
25. The method of claim 24 wherein the temperature at which step (d) is performed is about 90*C and the l temperature at which steps (c) and (e) is performed is about 70*C.
26. The method of claim 24 wherein said primers bind strongly to the strands of said target sequence and the extensions from said primers bind weakly to the strands
3C of said target sequence.
27. The method of claim 26 wherein the ratio of G and C to A and T in said primers ranges from about 1.5:1 to about 3.0:1.
28. The method of claim 24 wherein the reaction as time for steps (c)-(f) is from about 0.5 hours to about 3 hours.
29. The method of claim 24 wherein said nucleic acid is HIV-l DNA and said nucleoside triphosphates are deoxynucleoside triphosphates.
30. The method of claim 29 wherein said target S sequence is the nucleotide sequence 1317-1379 of pHXB2.
31. The method of claim 30 wherein said primer pair comprises the nucleotide sequences
5' GAAGGAGCCA CCCCACAAG 3' (SEQ ID NO: 1)
3' CCCCCCTGTA GTTCGTCGG 5'. (SEQ ID NO: 2)
32. The method of claim 29 wherein said target sequence is the nucleotide sequence 331-530 of pHXB2.
33. The method of claim 32 wherein said primer pair comprises the nucleotide sequences
5' GACATCGAGC TTGCTAGAAG 3' (SEQ ID NO: 4)
\ S
3' GGTGACGAAT TCGGAGTTAT 5'. (SEQ ID NO: 5)
34. A method for detecting or measuring a target nucleic acid sequence in a sample, wherein said target sequence consists of two complementary strands, comprising the steps of:
0 (a) amplifying said target sequence according to claim 25, wherein some of said nucleoside triphosphates are biotin-labeled, thereby producing nucleotide sequences
that are copies of said target nucleotide sequence and contain one or more biotin-labeled nucleotides;
(b) rendering said nucleotide sequences single-stranded;
S (c) contacting said sample containing said single-stranded nucleotide sequences with immobilized probes, each of which comprises a single-stranded polynucleotide attached to a solid support and capable of hybridizing with one of said single-stranded nucleotide
\0 sequences, for a sufficient time and under appropriate hybridizing conditions to permit said polynucleotides to hybridize with said single-stranded nucleotide sequences, thereby forming bound complexes of said polynucleotides and said single-stranded nucleotide sequences; and
IS (d) detecting or measuring the presence of biotin in said bound complexes.
35. The method of claim 34 wherein said detecting or measuring step comprises the steps of:
contacting said bound complexes with a °t ) detectable moiety that binds to biotin; and
detecting or measuring said detectable moiety.
36. The method of claim 34 wherein said nucleic acid is HIV-l DNA and said single-stranded polynucleotide of said probe comprises the sequence
2S~ 5' TTTAAACACC ATGCTAAACA CAGT 3'. (SEQ ID NO: 3)
37. A method for detecting or measuring the presence of a target nucleic acid sequence in a sample comprising the steps of:
(a) amplifying said target nucleic acid sequence through the formation of primer extension products that contain one or more biotin-labeled nucleotides;
(b) rendering said primer extension products single-stranded;
(c) contacting said sample containing said single-stranded sequences with immobilized probes, each of which comprises a single-stranded polynucleotide attached to a solid support and capable of hybridizing with one of said single-stranded nucleotide sequences, for a sufficient time and under appropriate hybridizing conditions to permit said polynucleotides to hybridize with said single-stranded nucleotide sequences, thereby forming bound complexes of said polynucleotides and said single-stranded nucleotide sequences;
(d) contacting said bound complexes with a first moiety that binds to biotin;
(e) adding a second moiety, comprising biotin bound to a detectable moiety, wherein the biotin in said second moiety binds to said first moiety; and
(f) detecting or measuring said detectable __? moiety.
38. The method of claim 37 wherein said first moiety is avidin and said detectable moiety is horseradish peroxidase.
39. The method of claim 37 wherein said amplifying 5 step is performed according to claim 1.
40. The method of claim 37 wherein said amplifying step is performed according to claim 24.
41. A primer pair for use in amplifying a target nucleic acid sequence of HIV-l DNA comprising the
10 nucleotide sequences
5' GAAGGAGCCA CCCCACAAG 3' (SEQ ID NO: 1)
3' CCCCCCTGTA GTTCGTCGG 5'. (SEQ ID NO: 2)
42. A primer pair for use in amplifying a target nucleic acid sequence of HIV-l DNA comprising the
I nucleotide sequences
5' GACATCGAGC TTGCTAGAAG 3' (SEQ ID NO: 4)
3' GGTGACGAAT TCGGAGTTAT 5'. (SEQ ID NO: 5)
43. A probe for use in detecting a nucleotide sequence complementary to a target nucleic acid sequence of
• Q HIV-l DNA, said probe comprising the nucleotide sequence
5' TTTAAACACC ATGCTAAACA CAGT 3' (SEQ ID NO: 3) or
5' CTCTCTTTAA ACACCATGCT AACACAGT 3' (SEQ ID NO: 6).
44. A kit for detecting or measuring the presence of a target nucleic acid sequence in a sample suspected of containing said sequence comprising, in a container:
S (a) biotin-labeled nucleoside triphosphates; and
(b) a primer pair consisting of two oligonucleotide primers, each primer comprising an oligonucleotide having a region that is complementary to lO and hybridizes with a different strand of said target sequence and being effective as a primer for nucleoside polymerization.
45. The kit of claim 44 further comprising a probe that is complementary to and hybridizes with said target ζ sequence.
46. The kit of claim 45 further comprising means for detecting or measuring said biotin.
47. The kit of claim 46 further comprising a nucleic acid polymerase.
30 48. The kit of claim 44 wherein said primer pair comprises the nucleotide sequences
5' GAAGGAGCCA CCCCACAAG 3' (SEQ ID NO: 1)
3' CCCCCCTGTA GTTCGTCGG 5'. (SEQ ID NO: 2)
49. The kit of claim 44 wherein said primer pair comprises the nucleotide sequences
5' GACATCGAGC TTGCTAGAAG 3' (SEQ ID NO: 4)
3' GGTGACGAAT TCGGAGTTAT 5'. (SEQ ID NO: 5)
5"
50. The kit of claim 45 wherein said probe comprises the nucleotide sequence
5' TTTAAACACC ATGCTAAACA CAGT 3'. (SEQ ID NO: 3)
51. A kit for detecting or measuring the presence of a target nucleic acid sequence in HIV-l DNA in a sample (0 suspected of containing said sequence comprising, in a container:
(a) biotin-labeled nucleoside triphosphates;
(b) a primer pair comprising the nucleotide sequences
IS 5' GAAGGAGCCA CCCCACAAG 3' (SEQ ID NO: 1)
3' CCCCCCTGTA GTTCGTCGG 5' (SEQ ID NO: 2)
and
(c) a probe comprising the nucleotide sequence
ϊlO 5' TTTAAACACC ATGCTAAACA CAGT 3'. (SEQ ID NO: 3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GR1992/000015 WO1994003635A1 (en) | 1992-08-04 | 1992-08-04 | Rapid amplification and detection of nucleic acids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GR1992/000015 WO1994003635A1 (en) | 1992-08-04 | 1992-08-04 | Rapid amplification and detection of nucleic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994003635A1 true WO1994003635A1 (en) | 1994-02-17 |
Family
ID=10938564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GR1992/000015 WO1994003635A1 (en) | 1992-08-04 | 1992-08-04 | Rapid amplification and detection of nucleic acids |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1994003635A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0617132A2 (en) * | 1993-03-26 | 1994-09-28 | Gen-Probe Incorporated | Probes and method to detect human immunodeficiency virus type 1 |
WO1997000330A2 (en) | 1995-06-13 | 1997-01-03 | Gottfried Himmler | Process for the transcriptionless amplification of nucleic acids |
EP0795612A2 (en) * | 1996-03-11 | 1997-09-17 | Johnson & Johnson Clinical Diagnostics, Inc. | Amplifying and detecting target nucleic acids using a post amplification incubation step |
US5712385A (en) * | 1989-07-11 | 1998-01-27 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
WO1998058086A3 (en) * | 1997-06-16 | 1999-03-11 | Abbott Lab | Nucleic acid primers and probes for detecting hiv-1 and hiv-2 |
US6589734B1 (en) | 1989-07-11 | 2003-07-08 | Gen-Probe Incorporated | Detection of HIV |
US6623920B1 (en) | 1999-07-09 | 2003-09-23 | Gen-Probe Incorporated | Detection of HIV-1 by nucleic acid amplification |
USRE38960E1 (en) | 1994-03-16 | 2006-01-31 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
US7105318B2 (en) | 1997-11-04 | 2006-09-12 | Roche Diagnostics Gmbh | Specific and sensitive nucleic acid detection method |
EP1890146A1 (en) * | 2005-06-01 | 2008-02-20 | Olympus Corporation | Method for detecting of nucleic acid |
US9562264B2 (en) | 2007-07-14 | 2017-02-07 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
US10077467B2 (en) | 2012-04-09 | 2018-09-18 | Envirologix Inc. | Compositions and methods for detecting a nucleic acid sequence in a sample comprising a primer oligonucleotide with a 3′-terminal region comprising a 2′-modified nucleotide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0511712A1 (en) * | 1991-04-30 | 1992-11-04 | Johnson & Johnson Clinical Diagnostics, Inc. | Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle |
-
1992
- 1992-08-04 WO PCT/GR1992/000015 patent/WO1994003635A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0511712A1 (en) * | 1991-04-30 | 1992-11-04 | Johnson & Johnson Clinical Diagnostics, Inc. | Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle |
Non-Patent Citations (2)
Title |
---|
J CLIN PATHOL, Volume 45, 1992, E S-F Lo et al, "Detection of hepatitis B pre-core mutant by allele specific polymerase chain reaction" * |
THE JOURNAL OF INFECTIOUS DISEASES, Volume 161, 1990, Kathleen D. Eisenach et al, "Polymerase Chain Reaction Amplification of a Repetitive DNA Sequence Specific for Mycobacterium tuberculosis" * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712385A (en) * | 1989-07-11 | 1998-01-27 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
US7083922B2 (en) | 1989-07-11 | 2006-08-01 | Gen-Probe Incorporated | Detection of HIV |
US6589734B1 (en) | 1989-07-11 | 2003-07-08 | Gen-Probe Incorporated | Detection of HIV |
US5856088A (en) * | 1989-07-11 | 1999-01-05 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
US6649749B2 (en) | 1993-03-26 | 2003-11-18 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
EP0617132A3 (en) * | 1993-03-26 | 1995-11-29 | Gen Probe Inc | Probes and method to detect human immunodeficiency virus type 1. |
EP0617132A2 (en) * | 1993-03-26 | 1994-09-28 | Gen-Probe Incorporated | Probes and method to detect human immunodeficiency virus type 1 |
US6252059B1 (en) | 1993-03-26 | 2001-06-26 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
USRE39007E1 (en) | 1994-03-16 | 2006-03-07 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
USRE38960E1 (en) | 1994-03-16 | 2006-01-31 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
WO1997000330A2 (en) | 1995-06-13 | 1997-01-03 | Gottfried Himmler | Process for the transcriptionless amplification of nucleic acids |
WO1997000330A3 (en) * | 1995-06-13 | 1997-04-10 | Gottfried Himmler | Process for the transcriptionless amplification of nucleic acids |
US6033881A (en) * | 1995-06-13 | 2000-03-07 | Himmler; Gottfried | Method for one step isothermal non-transcription based amplification of nucleic acids |
EP0795612A3 (en) * | 1996-03-11 | 1999-03-24 | Johnson & Johnson Clinical Diagnostics, Inc. | Amplifying and detecting target nucleic acids using a post amplification incubation step |
EP0795612A2 (en) * | 1996-03-11 | 1997-09-17 | Johnson & Johnson Clinical Diagnostics, Inc. | Amplifying and detecting target nucleic acids using a post amplification incubation step |
US6232455B1 (en) | 1997-06-16 | 2001-05-15 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
EP2067868A3 (en) * | 1997-06-16 | 2009-09-23 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
US5962665A (en) * | 1997-06-16 | 1999-10-05 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
WO1998058086A3 (en) * | 1997-06-16 | 1999-03-11 | Abbott Lab | Nucleic acid primers and probes for detecting hiv-1 and hiv-2 |
US7105318B2 (en) | 1997-11-04 | 2006-09-12 | Roche Diagnostics Gmbh | Specific and sensitive nucleic acid detection method |
US6623920B1 (en) | 1999-07-09 | 2003-09-23 | Gen-Probe Incorporated | Detection of HIV-1 by nucleic acid amplification |
US7723040B2 (en) | 1999-07-09 | 2010-05-25 | Gen-Probe Incorporated | Detection of HIV-1 by nucleic acid amplification |
EP1890146A4 (en) * | 2005-06-01 | 2009-05-13 | Olympus Corp | Method for detecting of nucleic acid |
EP1890146A1 (en) * | 2005-06-01 | 2008-02-20 | Olympus Corporation | Method for detecting of nucleic acid |
US9562264B2 (en) | 2007-07-14 | 2017-02-07 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
US9562263B2 (en) | 2007-07-14 | 2017-02-07 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
US9617586B2 (en) | 2007-07-14 | 2017-04-11 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
US9689031B2 (en) | 2007-07-14 | 2017-06-27 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
US10851406B2 (en) | 2007-07-14 | 2020-12-01 | Ionian Technologies, Llc | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
US10077467B2 (en) | 2012-04-09 | 2018-09-18 | Envirologix Inc. | Compositions and methods for detecting a nucleic acid sequence in a sample comprising a primer oligonucleotide with a 3′-terminal region comprising a 2′-modified nucleotide |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2071594C (en) | Methods for nucleic acid amplification | |
US6855523B2 (en) | Nucleic acid amplification method: ramification-extension amplification method (RAM) | |
US5876924A (en) | Nucleic acid amplification method hybridization signal amplification method (HSAM) | |
US5427929A (en) | Method for reducing carryover contamination in an amplification procedure | |
US5599662A (en) | Oliconucleotide primers and probes for the detection of HIV-1 | |
US6238866B1 (en) | Detector for nucleic acid typing and methods of using the same | |
AU662937B2 (en) | Nucleic acid target generation | |
EP0702090B1 (en) | Coamplification of target nucleic acids using volume exclusion agent, in reaction composition, test kit and test device useful therefor | |
US5569582A (en) | Rapid amplification and detection of nucleic acids | |
JP2000512160A (en) | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 | |
AU741141B2 (en) | Specific and sensitive method for detecting nucleic acids | |
EP0511712A1 (en) | Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle | |
EP1713925B9 (en) | Primers and probes for the detection of hiv | |
WO1994003635A1 (en) | Rapid amplification and detection of nucleic acids | |
USRE38442E1 (en) | Nucleic acid amplification method hybridization signal amplification method (HSAM) | |
CA2199213C (en) | Amplifying and detecting target nucleic acids using a post amplification incubation step | |
CA2075083A1 (en) | Rapid amplification and detection of nucleic acids | |
EP0418960A2 (en) | Nucleic acid detection method using unequal primer concentrations in polymerase chain reaction | |
JPH0852000A (en) | Simultaneous amplification method of nucleic acid | |
AU636499C (en) | Method for reducing carryover contamination in an amplification procedure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |